160 related articles for article (PubMed ID: 28924486)
1. Expression of transcription factors in MEN1-associated pancreatic neuroendocrine tumors.
Takeda Y; Fujita Y; Sakai K; Abe T; Nakamura T; Yanagimachi T; Sakagami H; Honjo J; Abiko A; Makino Y; Haneda M
Endocrinol Diabetes Metab Case Rep; 2017; 2017():. PubMed ID: 28924486
[TBL] [Abstract][Full Text] [Related]
2. Analysis of 55 patients with multiple endocrine neoplasia type 1-associated insulinoma from a single center in China.
Zhao Y; Yu J; Liu Y; Lyu L; Ping F; Xu L; Li W; Wang O; Xu Q; Wu W; Zhang H; Li Y
Orphanet J Rare Dis; 2022 Jun; 17(1):219. PubMed ID: 35698198
[TBL] [Abstract][Full Text] [Related]
3. Altered MENIN expression disrupts the MAFA differentiation pathway in insulinoma.
Hamze Z; Vercherat C; Bernigaud-Lacheretz A; Bazzi W; Bonnavion R; Lu J; Calender A; Pouponnot C; Bertolino P; Roche C; Stein R; Scoazec JY; Zhang CX; Cordier-Bussat M
Endocr Relat Cancer; 2013 Dec; 20(6):833-48. PubMed ID: 24157940
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.
Chiloiro S; Lanza F; Bianchi A; Schinzari G; Brizi MG; Giampietro A; Rufini V; Inzani F; Giordano A; Rindi G; Pontecorvi A; De Marinis L
Endocrine; 2018 May; 60(2):362-367. PubMed ID: 28567607
[TBL] [Abstract][Full Text] [Related]
5. [Multiple Endocrine Neoplasia I (Wermers Syndrome), Forms of Clinical Manifestation, 5 Case Studies].
Drbalová K; Herdová K; Krejčí P; Nývltová M; Solař S; Vedralová L; Záruba P; Netuka D; Bavor P
Vnitr Lek; 2016; 62(9 Suppl 3):140-149. PubMed ID: 27734708
[TBL] [Abstract][Full Text] [Related]
6. Mutation and Expression of Gene YY1 in Pancreatic Neuroendocrine Tumors and Its Clinical Significance.
Song YL; Xu J; Zhao DC; Zhang TP; Jin KZ; Zhu LM; Yu S; Chen YJ
Endocr Pract; 2021 Sep; 27(9):874-880. PubMed ID: 33705973
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.
Sadowski SM; Pieterman CRC; Perrier ND; Triponez F; Valk GD
Endocr Relat Cancer; 2020 Jun; 27(6):R145-R161. PubMed ID: 32229700
[TBL] [Abstract][Full Text] [Related]
8. Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas.
Hackeng WM; Schelhaas W; Morsink FHM; Heidsma CM; van Eeden S; Valk GD; Vriens MR; Heaphy CM; Nieveen van Dijkum EJM; Offerhaus GJA; Dreijerink KMA; Brosens LAA
Endocr Pathol; 2020 Jun; 31(2):108-118. PubMed ID: 32103422
[TBL] [Abstract][Full Text] [Related]
9. Synchronous Insulinoma and Glucagonoma: A Review of the Literature.
Damaskos C; Dimitroulis D; Garmpi A; Antoniou EA; Kouraklis G; Psilopatis I; Mavri M; Diamantis E; Marinos G; Kyriakos G; Farmaki P; Patsouras A; Kontzoglou K; Garmpis N
In Vivo; 2023; 37(6):2402-2408. PubMed ID: 37905620
[TBL] [Abstract][Full Text] [Related]
10. Hypersecretion of ACTH and PRL from pituitary adenoma in MEN1, adequately managed by medical therapy.
Uraki S; Ariyasu H; Doi A; Furuta H; Nishi M; Usui T; Yamaue H; Akamizu T
Endocrinol Diabetes Metab Case Rep; 2017; 2017():. PubMed ID: 28458907
[TBL] [Abstract][Full Text] [Related]
11. GHRH secretion from a pancreatic neuroendocrine tumor causing gigantism in a patient with MEN1.
Srirangam Nadhamuni V; Iacovazzo D; Evanson J; Sahdev A; Trouillas J; McAndrew L; R Kurzawinski T; Bryant D; Hussain K; Bhattacharya S; Korbonits M
Endocrinol Diabetes Metab Case Rep; 2021 Jun; 2021():. PubMed ID: 34156350
[TBL] [Abstract][Full Text] [Related]
12. Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas.
Marciello F; Di Somma C; Del Prete M; Marotta V; Ramundo V; Carratù A; de Luca di Roseto C; Camera L; Colao A; Faggiano A
Endocrine; 2014 Aug; 46(3):678-81. PubMed ID: 24385268
[TBL] [Abstract][Full Text] [Related]
13. Alpha cell-specific Men1 ablation triggers the transdifferentiation of glucagon-expressing cells and insulinoma development.
Lu J; Herrera PL; Carreira C; Bonnavion R; Seigne C; Calender A; Bertolino P; Zhang CX
Gastroenterology; 2010 May; 138(5):1954-65. PubMed ID: 20138042
[TBL] [Abstract][Full Text] [Related]
14. Distinct DNA Methylation Signatures in Neuroendocrine Tumors Specific for Primary Site and Inherited Predisposition.
Tirosh A; Killian JK; Petersen D; Zhu YJ; Walker RL; Blau JE; Nilubol N; Patel D; Agarwal SK; Weinstein LS; Meltzer P; Kebebew E
J Clin Endocrinol Metab; 2020 Oct; 105(10):3285-94. PubMed ID: 32706863
[TBL] [Abstract][Full Text] [Related]
15. What is the appropriate management of nonfunctioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?
Challis BG; Casey RT; Grossman A; Newell-Price J; Newey P; Thakker RV
Clin Endocrinol (Oxf); 2019 Dec; 91(6):708-715. PubMed ID: 31505044
[TBL] [Abstract][Full Text] [Related]
16. Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors.
Cejas P; Drier Y; Dreijerink KMA; Brosens LAA; Deshpande V; Epstein CB; Conemans EB; Morsink FHM; Graham MK; Valk GD; Vriens MR; Castillo CF; Ferrone CR; Adar T; Bowden M; Whitton HJ; Da Silva A; Font-Tello A; Long HW; Gaskell E; Shoresh N; Heaphy CM; Sicinska E; Kulke MH; Chung DC; Bernstein BE; Shivdasani RA
Nat Med; 2019 Aug; 25(8):1260-1265. PubMed ID: 31263286
[TBL] [Abstract][Full Text] [Related]
17. Different Hormonal Expression Patterns Between Primary Pancreatic Neuroendocrine Tumors and Metastatic Sites.
Kimura H; Ohtsuka T; Fujimoto T; Date K; Matsunaga T; Cases AI; Abe A; Mizuuchi Y; Miyasaka Y; Ito T; Oda Y; Nakamura M; Tanaka M
Pancreas; 2016 Aug; 45(7):947-52. PubMed ID: 26684862
[TBL] [Abstract][Full Text] [Related]
18. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.
Kornaczewski Jackson ER; Pointon OP; Bohmer R; Burgess JR
J Clin Endocrinol Metab; 2017 Jun; 102(6):1926-1933. PubMed ID: 28323985
[TBL] [Abstract][Full Text] [Related]
19. B-mode and contrast-enhancement characteristics of small nonincidental neuroendocrine pancreatic tumors.
Braden B; Jenssen C; D'Onofrio M; Hocke M; Will U; Möller K; Ignee A; Dong Y; Cui XW; Sãftoiu A; Dietrich CF
Endosc Ultrasound; 2017; 6(1):49-54. PubMed ID: 28218201
[TBL] [Abstract][Full Text] [Related]
20. Current and emerging therapies for PNETs in patients with or without MEN1.
Frost M; Lines KE; Thakker RV
Nat Rev Endocrinol; 2018 Apr; 14(4):216-227. PubMed ID: 29449689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
